



## Sustainable BioTech for the African region

Prof Robert S Langer

Massachusetts Institute of Technology, USA



Prof Robert Langer is highly regarded for his contributions to medicine and biotechnology. He is one of 12 Institute Professors at MIT and is considered a pioneer of many new technologies including the nanoparticle-based mRNA Moderna vaccine. Moderna is developing mRNA vaccines for a wide range of diseases beyond Covid-19.

Prof Langer's patents have been licensed or sublicensed to over 400 pharmaceutical, chemical, biotechnology and medical device companies. He will share his experience with us in view to support Biotechnology development in the African region. The new global challenges require the African region to engage into collaborative networks capitalizing on individual strengths for problem-solving. The Government of Mauritius has recently set-up its Mauritius Institute of Biotechnology to facilitate the setting-up of Biotechnology companies for the African region including vaccine production.

### To be covered during the talk and Q & A session

- Prof Langer's experience in the development of biotech companies, scaffolds for regenerative medicine and university spin-off
- Early investment in spin-off
- Contract manufacturing – Case of Moderna Vaccine
- The human capacity required for a regional Biotech Industry development
- R and D requirements for such an endeavor
- Timeline for making this happen
- The sustainability of this enterprise in the African context

**Date:** Monday 6<sup>th</sup> June 2022

**Time:** 16 55 – 17 55 (Time zone: GMT/UTC + 4)

**Zoom meeting:** Meeting ID: 836 6336 7491, Passcode: 838163

**Contact:** Prof Archana Bhaw-Luximon, CBBR, University of Mauritius

Email: a.luximon@uom.ac.mu